Novartis

General Information

Legal Entity Novartis Pharma AG provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis Group companies employ approximately 123,000 associates (2015) and operate in more than 140 countries around the world. The Novartis strategy is to deliver better outcomes for patients through science-based innovation. Neuroscience has a long history at Novartis. Novartis discovered and developed CNS medicines that have revolutionized medicine and transformed patient lives. Novartis emphasis is on pursuing cutting edge science and creating transformative technologies that lead to the development of new medicines for psychiatric, neurodegenerative, and neurodevelopmental diseases and conditions such as autism.

 

Role in AIMS-2-TRIALS

Novartis contributes to identify compounds for future trials within the consortium and advises on proposed methodologies.

Within the European Clinical Research Network, Novartis helps to develop a European infrastructure, to accelerate patient recruitment in clinical studies.  In order to quantify and validate Biomarkers in Autism, Novartis helps to identify patient subpopulation biomarkers.